XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
The original release is unavailable here.
XtalPi Holdings Limited on 6ix
Story so far
- XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
- XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform
- XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration
Earlier from XtalPi
- XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
- XtalPi Holdings Announces 2025 Interim Results
- XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
- XtalPi Holdings Limited to Announce 2025 Interim Results on August 27, 2025
- XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
Later from XtalPi
- XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
- Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant - Successful Launch of Advanced Automated Workstation at BASF
- XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117
- XtalPi Holdings Limited to Announce 2025 Annual Results on March 25, 2026
- XtalPi Holdings Announces Full Year 2025 Annual Results
Follow XtalPi into a list and get an email when it puts out news.
Follow XtalPi